WWW.KONF.X-PDF.RU
- , ,
 


Pages:     | 1 |   ...   | 7 | 8 ||

...

-- [ 9 ] --

88. Eisenkop, S.M. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study /S.M. Eisenkop, N.M. Spirtos, R.L. Friedman et al. // Gynecol Oncol.

2003. 90. P. 390-396.

89. Enomoto, T. Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? /T. Enomoto, C. Kuragaki et al. //ASCO. 2003. Abstr. 1797.

90. Fader, A. The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology group study /A. Fader, J. Java et al. // Gynecologic Oncology. 2014. 132.. P. 560-565.

91. Farmer, H. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy / H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, T.B.

Richardson, M.Santarosa, K.J.Dillon, I.Hickson, C.Knights, N.M. Martin, S.P. Jackson, G.C.Smith, A.Ashworth // Nature. 2005. 434 (7035). P. 917-21.

92. Friedlander, M, K.C. Hancock, D. Rischin, M.J. Messing, C.A. Stringer, G.M. Matthys et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer /M. Friedlander, K.C. Hancock, D. Rischin, M.J. Messing, C.A. Stringer, G.M. Matthys et al. //Gynecol Oncol. 2010. 119. P. 32-37.

93. Gadducci, A. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer /A. Gadducci, S. Cosio et al. // Clinical reviews in Oncology/Hematology. 2009. 69. P. 12-27.

94. Gelmon, K.A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study /K.A. Gelmon, M. Tischkowitz, H. Mackay et al. // Lancet Oncol. 2011. 12 (9). P. 852-861.

95. Gerestein, C. The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma /C. Gerestein, M. Eijkemans et al. // Gynaecological oncology. 2009. P. 372-388.

96. Gershenson, D.M. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant / D.M. Gershenson, C.C. Sun, D. Bodurka et al. // Gynecol Oncol. 2009. 114 (1). P. 48-52.

97. Gershenson, D.M. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum /D.M. Gershenson, C.C. Sun, R.B. Iyer et al.// Gynecol Oncol. 2012. 125 (3). P. 661-666.

98. Gershenson, D.M. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary /D.M. Gershenson, C.C. Sun, K.H. Lu et al. // Obstet Gynecol.

2006. 108. P. 361-368.

99. Gilks, C.B. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma /C.B. Gilks, D.N. Ionescu, S.E. Kalloger et al. // Hum Pathol. 2008. 39 (8). P. 1239-1251.

100. Goff, B.A. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease / B.A. Goff, R. Sainz de la Cuesta, H.G. Muntz et al. // Gynecol Oncol. 1996. 60 (3). P. 412-417.

101. Gonzalez, A. Increasing the chances for platinum-sensitive ovarian cancer patients /A. Gonzalez // Future oncol. 2013. N 9. 12. Suppl.1. P. 29-35.

102. Gonzalez-Martin, A.J. Randomized phase II trial of carboplatin versus

paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma:

a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study /A.J. Gonzalez-Martin, E. Calvo, I.Bover et al. // Ann Oncol. 2005. 16 (5). P. 749-755.

103. Gordon, A.N. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study /A.N. Gordon, N. Finkler, R.P. Edwards et al. // Int J Gynecol Cancer. 2005. 15 (5). P. 785-792.

104. Gordon, A.N. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan /A.N. Gordon, J.T. Fleagle, D. Guthrie et al. // J Clin Oncol. 2001. 19 (14). P. 3312-3322.

105. Gordon, M.S. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status /M.S. Gordon, D. Matei, C. Aghajanian et al. // J Clin Oncol. 2006. 24 (26). P. 4324-4332.

106. Gore, M. Treatment of relapsed carcinoma of ovary with cisplatin or carboplatin following initial treatment with these compounds /M. Gore, I. Fryatt et al. // Gynecologic Obcology. 1990. Vol. 36, N 2. P. 207-211.

107. Gotlieb, W.H. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study /W.H. Gotlieb, F. Amant, S. Advani, C. Goswami, H. Hirte, D. Provencher et al.//Lancet Oncol. 2012. 13.

P. 154-162.

108. Griffiths, C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma /C.T. Griffiths // Natl Cancer Inst Monogr. 1975. 42. P. 101-104.

109. Gronlund, B. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer /B. Gronlund, C. Hogdall, H.H. Hansen et al. // Gynecol Oncol. 2001. 83 (1). P. 128-134.

110. Hakes, T.B. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma /T.B. Hakes, E. Chalas, W.J. Hoskins et al. // Gynecol Oncol. 1992. 45 (3). P. 284-289.

111. Hall, G.D. Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study / G.D. Hall, J.M. Brown, R.E. Coleman et al. // Br J Cancer. 2004. 91 (4).

P. 621-626.

112. Harano, K. Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016) /K. Harano, F. Terauchi et al. // Annals of Oncology. 2014. 25. P. 251-257.

113. Heintz, A.P. Carcinoma of the ovary.FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer /A.P. Heintz, F. Odicino, P. Maisonneuve et al. // Int J Gynaecol Obstet. 2006. 95 (Suppl. 1). S161-S192.

114. Heintz, A.P. Carcinoma of the ovary /A.P. Heintz, F. Odicino, P. Maisonneuve et al. // Int J Gynaecol Obstet. 2006. 95 (Suppl.1). S161-192, with permission.

115. Herzog, T.J. Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study /T.J. Herzog, J.B. Vermorken, E. Pujade-Lauraine et al. // Gynecol Oncol. 2011. 122 (2). P. 350-355.

116. Herzog, T.J. The current treatment of recurrent ovarian cancer /T.J. Herzog // Curr Oncol Rep. 2006. 8 (6). P. 448-454.

117. Hoskins, P.J. Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation /P.J. Hoskins, N. Le, B.Gilks et al. // J Clin Oncol. 2012. 30 (14). P. 1656-1662.

118. Hoskins, P.J. Identifying patients unlikely to benefit from further chemotherapy: a descriptive study of outcome at each relapse in ovarian cancer /P.J. Hoskins, N. Le // Gynecol Oncol. 2005. 97 (3). P. 862-869.

119. Hoskins, W.J. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a gynecologic oncology group study /W.J. Hoskins, B.N. Bundy, J.T. Thigpen et al. // Gynecol Oncol.

1992. 47. P. 159-166.

120. Hoskins, W.J. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal.A Gynecologic Oncology Group Study /W.J. Hoskins, W.P. McGuire, M.F. Brady et al. // Gynecol.

Oncol. 2009. 117 (2). P. 440-450.

121. Hurteau, J.A. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane

chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF):

A Gynecologic Oncology Group Study /J.A. Hurteau, M.F. Brady, K.M. Darcy et al. // Gynecol. Oncol. 2010. 119 (3). P. 444-450.

122. ICON7: final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer // Eur J Cancer. 2013. 49 (Suppl 3). LBA 6.

123. Integrated genomic analyses of ovarian carcinoma// Nature. 2011. 474. P. 609-615.

124. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial // Lancet. 2002. Aug 17. 360 (9332). P. 505-15.

125. Karami, F. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer / F. Karami, P. Mehdipour // Biomed Res Int. 2013. C.928562.

126. Karlan, B.Y. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer /B.Y. Karlan, A.M. Oza, G.E. Richardson, D.M. Provencher, V.L. Hansen, M. Buck et al. // J Clin Oncol. 2012. 30. P. 362-371.

127. Kastumata, N. Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer: JGOG 3016 trial /N. Kastumata, M. Yasuda, S Isonishi et al. // ASCO. 2012.

Abstract

#5003 (J Clin Oncol. June 2012).

128. Kaye, S. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval /S. Kaye, N. Colombo et al. // Ann Oncol. 2011. 71. P. 320-326.

129. Kobel, M. On behalf of the Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency, Vancouver, B.C. Differences in tumor cell type in low versus high stage ovarian carcinomas /M. Kobel, S. Kalloger, D.G. Huntsman et al. // Int J Gynecol Pathol. 2010. 29. P. 203-211.

130. Kobel, M. Ovariam Carcinoma subtypes are different Diseases:

Implications for Biomarker Studies /M. Kobel, S. Kalloger et al. // PLOS medicine. 2008. December 2.

131. Kozary, C.L. Cancer of the ovary. In: SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1998-2001. Available at: http:// seercancer.gov/publications/survival/surv_ovary. pdf (Accessed September 19, 2012.)

132. Kurman, R. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-Shifting the paradigm /R. Kurman, I. Shin et al. // Human. 2011. 42. P. 918-931.

133. Lacour, R.A. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma /R.A. Lacour, E. Euscher, E.N. Atkinson et al. // Int J Gynecol Cancer. 2011. 21 (3). P. 517-522.

134. Lambert, H.E. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study /H.E. Lambert, G.J. Rustin, W.M. Gregory et al. // Ann Oncol. 1997. 8 (4).

P. 327-333.

135. Ledermann, J.A. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer /J.A. Ledermann, A. Hackshaw, S. Kaye, G. Jayson, H. Gabra, I. McNeish et al. // J Clin Oncol. 2011. 29. P. 3798-3804.

136. Ledermann, T.J.P. J.A. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial /T.J.P. J.A. Ledermann, F.A. Raja, A. Embleton, G.J.S. Rustin, G. Jayson, S.B. Kaye et al.// Eur J Cancer. 2013. 49 (Suppl 3). LBA10.

137. Lee, C. Carboplatin-paclitaxel-induced leucopenia and neuropathy predict progression-free survival in recurrent ovarian cancer /C. Lee, H.Gurney et al. // British Journal of cancer. 2011. 105. P. 360-365.

138. Lee, C. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer /C. Lee, R. Simes et al. // Annals of Oncology. 2013. 24. P. 937-943.

139. Lee, C.K. Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer / C.K. Lee, R.J.Simes, C. Brown et al. // Br J Cancer. 2011. 105 (8). P. 1144-1150.

140. Lee, P. Expression of progesterone receptor is a favorable prognostic market in ovarian cancer / P. Lee, D. Rosen et al. // Gynecologic Oncology. 2005. 96. P. 771-677.

141. Lesnock, J.L. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study /J.L. Lesnock et al. //British journal of cancer. 2013. . 108. 6.

P. 1231-1237.

142. Leunen, K. Does paclitaxel-carboplatin chemotherapy in a dose-dense regimen enhance survival of BRCA-related ovarian cancer patients? /K. Leunen et al.

//International Journal of Gynecological Cancer. 2009. . 19, N 9. P. 1501-1504.

143. Levin, L. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma /L. Levin, W.M. Hryniuk // J Clin Oncol. 1987. 5 (5). P. 756-767.

144. Lortholary A, Largillier R, Weber B, et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) /A. Lortholary, R. Largillier, B. Weber et al. //Ann Oncol. 2012. 23 (2). P. 346-352.

145. Lydiksen, L. Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer? / L. Lydiksen, S. Jensen-Fangel et al. //Gynecologic oncology. 2014. N 6. 4C.

146. Mackay, H.J. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer /H.J. Mackay, M.F. Brady, A.M. Oza et al. // Int J Gynecol Cancer. 2010. 20 (6). P. 945-952.

147. Makhija, S. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer /S. Makhija, L.C. Amler, D. Glenn et al. // J Clin Oncol. 2010. 28 (7). P. 1215-1223.

148. Markman, M. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group /M. Markman, B.N. Bundy, D.S. Alberts et al. // J Clin Oncol. 2001. 19 (4). P. 1001-1007.

149. Markman, M. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report /M. Markman, K.A. Iseminger, K.D. Hatch et al. // Gynecol Oncol. 1996. 62. P. 4-6.

150. Markman, M. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial /M. Markman, P.Y. Liu, J. Moon et al. // Gynecol Oncol. 2009. 114 (2). P. 195-198.

151. Markman, M. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial /M. Markman, P.Y. Liu, S. Wilczynski et al. // J Clin Oncol. 2003. 21 (13). P. 2460-2465.

152. Markman, M. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design /M. Markman, J. Markman, K. Webster et al. // J Clin Oncol. 2004. 22 (15). P. 3120-3125.

153. Markman, M. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin /M. Markman, R. Rothman, T. Hakes et al. //lin Oncol.

1991. 9 (3). P. 389-393.

154. Markman, M. maintenance chemotherapy in the management of epithelial ovarian cancer. Cancer Metastasis rev. 2015 online published.

155. Markman, M. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial / M. Markman, P. Liu et al. // Journal of Clinical Oncology. 21. P. 2460-2465.

156. Matsuo, K. Patient reported symptoms and survival in ovarian cancer /K. Matsuo, E.H. Ahn, C.P. Prather et al. // Int J Gynecol Cancer. 2011. 21 (9). P. 1555-1565.

157. Matulonis, U.A. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer /U.A. Matulonis, S. Berlin, P. Ivy et al. // J Clin Oncol. 2009.

27. P. 5601-5606.

158. McGuire, W.P. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage Ill and stage IV ovarian cancer /W.P. McGuire, W.J. Hoskins, M.F. Brady et al. // N Engl Med. 1996. 334 (1). P. 1-6.

159. Misset, J.L. Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs.cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients /J.L. Misset, P. Vennin, P.H. Chollet et al. // Ann Oncol. 2001. 12 (10). P. 1411-1415.

160. Modified with permission from Tavassoli FA, Devilee P. Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumors. Lyon, France: IARC Press, 2003. P. 114.

161. Monk, A.P.B.J. A phase III, randomized, double-blind trial ofweekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1 /A.P. B.J. Monk, I. Vergote, F. Raspagliesi, K. Fujiwara, D.S. Bae, A. Oaknin et al. // Eur J Cancer. 2013. 49 (Suppl 3). LBA 41.

162. Monk, B.J. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis /B.J. Monk, T.J. Herzog, S.B. Kaye et al. // Eur J Cancer. 2012.

163. Morotti, M. Pemetrexed disodium in ovarian cancer treatment / M. Morotti, M. Valenzano Menada, P.L. Venturini, S. Mammoliti, S. Ferrero // Expert Opin Investig Drugs. 2012. 21 (4). P. 437-449.

164. Muggia, F.M. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study /F.M. Muggia, P.S. Braly, M.F. Brady et al. // J Clin Oncol. 2000. 18 (1). P. 106-115.

165. Mutch, D.G. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer /D.G. Mutch, M. Orlando, T. Goss et al. // J Clin Oncol. 2007. 25 (19). P. 2811-2818.

166. Obermair, A. A new prognostic model for FIGO stage 1 epithelial ovarian cancer /A. Obermair, A. Fuller, E. Lopez-Varela et al. // Gynecol Oncol. 2007. 104 (3). P. 607-611.

167. Omura, G. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study /G. Omura, J.A. Blessing, C.E. Ehrlich et al. // Cancer. 1986. 57 (9). P. 1725-1730.

168. Oza, M.TJP, A.M. Swart, W. Schrder, E. Pujade-Lauraine, H. Havsteen, P. Beale et al.

169. Oza, TJP, A.M. Swart, W. Schrder, E. Pujade-Lauraine, H. Havsteen, P.

Beale et al.

170. Paley, P. Vascular endothelial growth factor expression in early stage ovarian carcinoma /P. Paley, B. Goff et al. // Cancer. 1997. Vol. 80 (1). P. 98-106

171. Parmar, M.K. Paclitaxel plus platinum-based chemotherapy versus

conventional platinum-based chemo-therapy in women with relapsed ovarian cancer:

the ICON4/AGO-OVAR-2.2 trial / M.K. Parmar, J.A. Ledermann, N. Colombo et al. // Lancet. 2003. 361 (9375). P. 2099-2106.

172. Parvin, J.D. BRCA 1 at a branch point / J.D. Parvin // Proc Natl Acad Dci USA. 2001. 98 (11). P. 5952-4.

173. Pearce, C.L. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies /C.L. Pearce, C. Templeman, M.A. Rossing et al. // Lancet Oncol. 2012. 13. P. 385-394.

174. Pecorelli, S. Phase Ill trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1 /S. Pecorelli, G. Favalli, A. Gadducci et al. // J Clin Oncol. 2009. 27 (28). P. 4642-4648.

175. Perez-Gracia, J.L. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research / J.L. Perez-Gracia, E.M. Carrasco //Gynecol Oncol. 2002. 84. P. 201-209.

176. Perren, T. A phase 3 trial of bevacizumab in ovarian cancer /T. Perren, A. Swart et al. // New England Journal of medicine. 2011. 365. P. 2484-2496.

177. Pfisterer, J. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG /J. Pfisterer, M. Plante, I. Vergote et al. // J Clin Oncol. 2006. 24 (29). P. 4699-4707.

178. Pfisterer, J. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO /J. Pfisterer, B. Weber, A. Reuss et al.

// J Natl Cancer Inst. 2006. 98 (15). P. 1036-1045.

179. Piccart, M.J. Randomized intergroup trial of cisplatin-paclitaxel versus

cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer:

three-year results /M.J. Piccart, K. Bertelsen, K. James et al. // J Natl Cancer Inst. 2000.

92 (9). P. 699-708.

180. Piccart, M.J. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy /M.J. Piccart, A. Floquet, G. Scarfone et al. // Int J Gynecol Cancer. 2003. 13 (suppl. 2). P. 196-203.

181. Piccart, M.J. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group /M.J. Piccart, J.A. Green, A.J. Lacave et al. // J Clin Oncol. 2000. 18 (6). P. 1193-1202.

182. Pignata, S. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial /S. Pignata, G. Scambia, G. Ferrandina et al. // J Clin Oncol. 2011. 29 (27). P. 3628-3635.

183. Pignata, S. Carboplatin plus paclitaxel once a week versus 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomized, multicentre, open-label, phase 3 trial /S. Pignata, G. Scambia et al. // Lancet Oncol. 2014. 15.

P. 396-405.

184. Posadas, E.M. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer /E.M. Posadas, M.S. Liel, V. Kwitkowski et al. // Cancer. 2007. 109 (7). P. 1323-1330.

185. Psyrri, A. Effect of Epidermal Growth factor receptor Expression level on Survival in patients with Epithelial Ovarian cancer / A. Psyrri, M. Kassar et al. // Clin.

cancer. res. 2005. Dec. 15. 11. P. 8637.

186. Pujade-lauraine, E. AURELIA: a randomized phase III trial evaluating bevacizumab plus chemotherapy for platinum-resistant ovarian cancer /E. Pujade-lauraine, F. Hilpert et.al. // Journal of Clinical Oncology. 2012. 30 (suppl: LBA 5002).

187. Rendina, G.M. Steroid receptors and prognostic therapy in ovarian endometrioid carcinoma /G.M. Rendina, C. Donadio, M. Giovannini // Eur J Gynaecol Oncol. 1982. 3. P. 241-246.

188. Rosa, D. The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma / D. Rosa, A. Clamp et al. // Eur J. Sur. Oncol.

2006. Jun. 32. P. 588-91.

189. Rose, P.G. Secondary surgical cytoreduction for advanced ovarian carcinoma /P.G. Rose, S. Nerenstone, M.F. Brady et al. // N Engl J Med. 2004. 351. P. 2489-2497.

190. Rubin, S.C. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1 / S.C. Rubin, I. Benjamin, K. Behbakht et al. // N Engl J Med. 1996. 335 (19). P. 1413-1416.

191. Rustin, G.J. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial / G.J. Rustin, M.E. van der Burg, C.L. Griffin et al. // Lancet. 2010. 376 (9747). P. 1155-1163.

192. Rutten, M. Development and internal validation of a prognostic model for survival after debulking surgery for epithelial ovarian cancer / M. Rutten, J. Bolding et al. // Gynecologic Oncology. 2014. 135. P. 13-18.

193. Sabbatini, P. Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy / P. Sabbatini, D. Mooney, A. Lasonos et al. // Int J Gynecol Cancer. 2007. 17 (3). P. 589-594.

194. Safra, T. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer / T. Safra, O. Rogowski, F.M. Muggia //International Journal of Gynecological Cancer. 2014. Vol. 24, N 3.

P. 488-495.

195. Schilder, R.J. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash / R.J. Schilder, H.B. Pathak, A.E. Lokshin et al. // Gynecol Oncol. 2009. 113 (1). P. 21-27.

196. Sehouli, J. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicn (PLDC): A randomized phase III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR) /J. Sehouli, W. Meier, P. Wimberger et al. // ASCO Annual Meeting. 2012. Abstract 5500.

197. Sehouli, J. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer; current evidence and future perspectives / J. Sehouli, V. Alfaro et.al. // Annals of Oncology. 2012. 23. P. 556-562.

198. Seiden, M.V. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies / M.V. Seiden, H.A. Burris, U. Matulonis et al.

//Gynecol Oncol. 2007. 104 (3). P. 727-731.

199. Seidman, J.D. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis /J.D. Seidman, R.J. Kurman, B.M. Ronnett //Am J Surg Pathol. 2003. 27. P. 985-993.

200. Seward, S. Primary debulking surgery and neoadjuvant chemotherapy in the threatment of advanced epithelial ovarian carcinoma / S. Seward, I. Winer// Cancer Metastasis rev. 2015.

201. Siegel, K. Cancer statistics, 2013 /K. Siegel, D. Naishadham, A. Jemal // CA Cancer J Clin. 2013. 63. P. 11-30.

202. Sieh, W. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study / W. Sieh, M. Kobel et al. // Lancet Oncol. 2013. 14. P. 853-62.

203. Skaznik-Wikiel, M.E. Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report / M.E. Skaznik-Wikiel, P. Sukumvanich, S. Beriwal et al. // Int J Gynecol Cancer. 2011. 21 (6). P. 1013-1017.

204. Skaznik-Wikiel, M.E. Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report / M.E. Skaznik-Wikiel, P. Sukumvanich, S. Beriwal et al. // Int J Gynecol Cancer. 2011. 21 (6). P. 1013-1017.

205. Sorbe, B. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment /B. Sorbe // Int J Gynecol Cancer. 2003. 13 (3). P. 278-286.

206. Spriggs, D.R. Phase III randomized trial of intravenous cisplatin plus a 24or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study / D.R. Spriggs, M.F. Brady, L.Vaccarello et al. // J Clin Oncol. 2007.

25 (28). P. 4466-4471.

207. Steffensen, K.D. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients / K.D. Steffensen, M. Waldstrom, I. Brandslund et al. // Int J Gynecol Cancer. 2011. 21 (6). P. 1040-1047.

208. Stoeckle, E. Progress in Survival Outcomes in Patients with Advanced Ovarian Cancer Treated by Neo-Adjuvant Platinum/Taxane-Based Chemotherapy and late Interval Debulking Surgery / E. Stoeckle, L. Bourdarias, F. Guyon et al. // Ann.

Surg. Oncol. 2014. 21. P. 629-636.

209. Stone, R.L. Paraneoplastic thrombocytosis in ovarian cancer / R.L. Stone, A.M. Nick, I.A. McNeish et al. // N Engl J Med. 2012. 366 (7). P. 610-618.

210. Storey, D.J. Endometrioid epithelial ovarian cancer: 20 years of prospectively collected data from a single center / D.J. Storey, R. Rush, M. Stewart et al. // Cancer. 2008. 112. P. 2211-2220.

211. Storey, D.J. Endometrioid epithelial ovarian cancer: 20 years of prospectively collected data from a single center / D.J. Storey, R. Rush, M. Stewart et al. // Cancer. 2008. 112. P. 2211-2220.

212. Sung, P. Global distribution pattern of histological subtypes of epithelial ovarian cancer: A database analysis and systematic review / P. Sung, Y.Chang et al. // Gynecologic Oncology. 2014. 133. P. 147-154.

213. Takano, M. Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases / M. Takano, Y. Kikuchi, K. Kudoh et al. // IntJ Clin Oncol. 2011. 16 (5). P. 605-609.

214. Takano, M. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging / M. Takano, Y. Kikuchi, N. Yaegashi et al. // Br J Cancer. 2006. May 22. 94 (10). P. 1369-1374.

215. Tangjitgamol, S. Expressions of Estrogen and progesterone Receptors in Epithelial Ovarian cancer: A Clinicopathologic Study / S. Tangjitgamol, S. Manusirivithaya et al. // IJGC. 2009. May. Vol. 19. Issue 4. P. 620-627.

216. Tarakura, S. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study / S. Tarakura, M. Takano, F. Takahashi et al. // Int J Gynecol Cancer. 2010. 20 (2). P. 240-247.

217. Tas, F. Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer / F.Tas, S. Karabulut et al. // Cancer Chemother. Pharmacol. 2014. 73. P. 631-637.

218. ten Bokkel Huinink, W. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer / W. ten Bokkel Huinink, M. Gore, J. Carmichael et al. // J Clin Oncol. 1997. 15 (6). P. 2183-2193.

219. Teramukai, S. PIEPOC: A New Prognostic Index for Advanced Epithelial Ovarian cancer-Japan Multinational Trial Organization OC01-01 / S. Teramukai, K. Ochiai et al. // Journal of Clinical Oncology. 2007. Vol. 25, N 22.

220. Tewari, K. Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: An exploratory study of the Gynecologic Oncology Group / K. Tewari, J. Java et al. // Gynecologic Oncology. 2014. N7. 4 c.

221. Thigpen, J.T. Phase II trial of paclitaxel in with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study / J.T. Thigpen, J. Blessing et al.// Lournal of Clinical Oncology. 1994. Vol.12, N 9.

P. 1748-1753.

222. Tothill, R. Novel molecular Subtypes of serous and endometrioid Ovarian cancer Linked to clinical outcome / R. Tothill, A.Tinker et al. // Clin. cancer res. 2008. August 15. 14. P. 5198.

223. Ushijima, K. Treatment for Recurrent Ovarian cancer-At First relapse.

Review Article / K. Ushijima // Journal of Oncology. 2010. Vol. 2010. Article ID 497429. 7 pages.

224. Van de Laar, R. External validation of three prognostic models for overall survival in patients with advanced-stage epithelial ovarian cancer / R.Van de Laar, J. Inthout et al. // British journal of cancer. 2014. 110. P. 42-48.

225. Van Der Burg, M.E.L. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer / M.E.L.Van Der Burg, M. Van Lent, M. Buyse et al.// N Engl J Med. 1995. 332. P. 629-634.

226. Vara, M.A. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group / M.A. Vara, F.B. Stehman, B.N. Bundy et al. // J Clin Oncol. 2003. 21 (15). P. 2849-2855.

227. Vasey, P.A. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma / P.A. Vasey, G.C. Jayson, A. Gordon et al. // J Natl Cancer Inst. 2004. 96 (22). P. 1682-1691.

228. Vergote, I. Randomized Phase III study of Erlotinib versus Observation in Patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian cancinoma: A European Organisation for research and treatment of Cancer-Gynaecological Cancer Group, and Gynecologic cancer Intergroup Study / I. Vergote, A. Jimeno et al. // Journal of Clinical Oncology. 2014. Vol. 32, N 4. P. 320-326.

229. Vergote, I. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma / I. Vergote, J. De Brabanter, A. Fyles et al. // Lancet. 2001. 357 (9251). P. 176-182.

230. Vergote, I. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer / I. Vergote, C.G. Troupe, F.Amant et al. // N Engl J Med. 2010.

363. P. 943-953.

231. Vergote, I.B. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC- GCG study / I.B. Vergote, F. Joly, D. Katsaros et al. // J Clin Oncol. 2012. 30 (suppl; abstr LBA5000).

232. Verheijen, R.H. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission / R.H. Verheijen, L.F. Massuger, B.B. Benigno et al. // J Clin Oncol. 2006. 24 (4). P. 571-578.

233. Wagner, U. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6) / U. Wagner, A. du Bois, J. Pfisterer et al. // Gynecol Oncol. 2007. 105 (1). P. 132-137.

234. Wagner, U. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs. paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients / U. Wagner, C. Marth, R. Largillier et al.

// Br J Cancer. 2012. 107 (4). P. 588-591. doi: 10.1038/ bjc. 2012.307.

Epub 2012. Jul 26.

235. Walsh, T. Mutations in 12 genes for inherited ovarian,fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing / T. Walsh, S. Casadei et al. // Proc. Natl Acad. Sci. USA. 2011. 108. P. 18032-8037

236. Wang, Y. Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a meta-analysis /Y. Wang, D. Wang et al. // Tumor Biol. 2013.

237. Winter, W.E. 3rd Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study / W.E. 3rd Winter, G.L. Maxwell, C. Tian et al. // J Clin Oncol. 2007. 25 (24). P. 3621-3627.

238. Winter, W.E. 3rd Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study / W.E. 3rd Winter, G.L. Maxwell, C. Tian et al. // J Clin Oncol. 2007. 25 (24). P. 3621-3627.

239. Winter, W.E. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecological Oncology Group study / W.E. Winter, G.L. Maxwell, C. Tian et al. // J Clin Oncol. 2008. 26. P. 83-89.

240. Witteveen, A.L.P. Final overall survival (OS) results from AURELIA, an open-label randomised phase IIItrial of chemotherapy (CT) with or without bevacizumab (BEV) for platinumresistant recurrent ovarian cancer (OC) / A.L.P. Witteveen, T. Fehm, A. Poveda, A. Reuss, H. Havsteen, F. Raspagliesi et al. // Eur J Cancer. 2013. 49 (Suppl 3). LBA 5.

241. Wright, J. Defining the limits of radical cytoreductive surgery for ovarian cancer / J. Wright, S.N. Lewin, I. Deutsch et al. // Gynecol Oncol. 2011. 123. P. 467-473.

242. Wright, J. Defining the limits of radical cytoreductive surgery for ovarian cancer / J. Wright, S.N. Lewin, I. Deutsch et al. //Gynecol Oncol. 2011. 123.

243. Yang, D. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer / D. Yang, S. Khan, Y. Sun et al. // JAMA. 2011. 306 (14). P. 1557-1565.

244. Yang, D. Association between BRCA2 but not BRCA1 mutations and beneficial Survival, Chemotherapy sensitivy, and gene Mutator Phenotype in Patients with ovarian cancer / D. Yang, S. Khan et al. // JAMA. 2011. October 12. 306 (14). P. 1557-1565.

245. Yap, T.A. Beyond chemotherapy: targeted therapies in ovarian cancer / T.A. Yap, C.P. Carden, S.B. Kaye // Nat Rev Cancer. 2009. 9 (3). P. 167-181.

246. Yoshino, K. Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients / K. Yoshino, T. Enomoto, M. Fujita et al. // IntJ Clin Oncol. 2011.

247. Zaino, R.J. Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study /R.J. Zaino, M.F. Brady, S.M. Lele et al. // Cancer. 2011. 117 (3). P. 554-562.

248. Zheng, H. Hormonal therapy in ovarian cancer / H. Zheng, J.J. Kavanagh, W. Hu et al. // Int J Gynecol Cancer. 2007. 17. P. 325-338.

249. Zhong, Q. Effects of BRCA1-and BRCA2-related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis /Q. Zhong, H. Peng et al. // Clin. Cancer Res. 2014. 21 (1). P. 211-20.



Pages:     | 1 |   ...   | 7 | 8 ||
 

:

13.00.01 , : , ,...

, - 06.01.05 ...

- 25.00.25 : ...

() TETRANYCHUS ATLANTICUS MGREGOR : 06.01.07 : ...

( POTENTILLA L., ROSACEAE) 03.02.01 : , .. ... 1. ...

06.02.02 , , , : , , ...

. () 03.02.08 , .. 2015...

- 03.01.06 ( ) , .. 2014 .....

- 03.02.02 : , 2015 1 2 2.1 ...

- - 03.02.08 ( ) : ...

14.02.01 : , ...

03.02.14 2015 ..3 I. . 1.1....

. 14.02.02 : , , 20 ...

- - 03.02.06 , .. 2015 ...

: 06.02.02 , , , :...

03.02.07 06.01.05 ...

BRUCELLA ABORTUS 19 BA, FRANCISELLA TULARENSIS 15 , YERSINIA PESTIS EV 03.02.03 :...







 
<<     |    
2016 www.konf.x-pdf.ru - - , ,

, .
, , , , 1-2 .